

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Resonance Health Limited
ABN 96 006 762 92

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mitchell Wells
Date of last notice	16 November 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest: 1. Mitchell Wells 2. Biggles Pty Ltd ATF Biggles Investment Trust (Mr. Wells is a Director of Biggles Pty Ltd)
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	28 November 2019
No. of securities held prior to change	Mitchell Wells - 600,000 shares
Class of securities acquired	Unlisted Options

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	1. Mitchell Wells 600,000 shares 2. Biggles Pty Ltd ATF Biggles Investment Trust: 1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Unlisted Options - Resolution 6 approved by shareholders at the Annual General Meeting held on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Resonance Health Limited
ABN 96 006 762 492

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Martin Blake
Date of last notice	16 June 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect Interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	BLAKE NOMINEES PTY LTD <M AND T SUPER FUND A/C> Superannuation Fund of Dr Martin Blake
Date of change	28 November 2019
No. of securities held prior to change	Direct – 3,798,590 shares Indirect – 2,666,087 shares
Class	Unlisted Options
Number acquired	1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Indirect – 2,666,087 shares Direct – 3,798,590 shares - 1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 - 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 - 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Unlisted Options - Resolution 4 approved by shareholders at the Annual General Meeting held on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	n/a
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Resonance Health Limited
ABN 96 006 762 92

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Simon Panton
Date of last notice	05 February 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect Interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Direct interest – Southam Investments 2003 Pty Ltd (Warwickshire Investments A/C) Indirect interest – The Design Counsel Pty Ltd (The Design Counsel S/F A/C)
Date of change	28 November 2019
No. of securities held prior to change	Direct – 73,000,000 shares Indirect – 546,350 shares
Class	Unlisted Options
Number acquired	1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	<p>Direct – 73,000,000 shares</p> <p>Indirect : The Design Counsel Pty Ltd (The Design Counsel S/F A/C)</p> <ul style="list-style-type: none"> - 546,350 shares - 1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 - 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 - 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Unlisted Options - Resolution 7 approved by shareholders at the Annual General Meeting held on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Resonance Health Limited
ABN 96 006 762 92

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Travis Baroni
Date of last notice	11 December 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect Interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Direct interest – Travis Baroni
Date of change	28 November 2019
No. of securities held prior to change	500,000 shares
Class	Unlisted Options
Number acquired	1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Direct – 500,000 shares 1,000,000 Unlisted Options exercisable at \$0.15 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.175 expiring 28 November 2022 1,000,000 Unlisted Options exercisable at \$0.20 expiring 28 November 2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Unlisted Options - Resolution 5 approved by shareholders at the Annual General Meeting held on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.